## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.14 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($180.79)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Charles River Laboratories stock hits 52-week high at 200.51 USD**
- Source: Investing.com | 20251215T145604 | Bullish | Relevance: 100%
- Charles River Laboratories (CRL) stock has reached a new 52-week high of $200.51, reflecting a 1.56% increase over the past year and a 29.16% return over the last six months. This surge is underpinned by strong investor confidence, analyst expectations of profitability for the current year with a forecasted EPS of $10.34, and strategic share buybacks by management. Recent developments include multiple analyst upgrades and a concluded SEC investigation without enforcement action, contributing to its positive trajectory.

**2. JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating**
- Source: marketscreener.com | 20251215T140303 | Somewhat-Bullish | Relevance: 100%
- JPMorgan has adjusted its price target for Charles River Laboratories International (NYSE: CRL) to $190, an increase from the previous $165, while maintaining a Neutral rating on the stock. This update reflects the firm's revised outlook for the company, following other analyst activities for CRL. The article also provides recent news headlines and stock performance data for Charles River Laboratories International.

**3. Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort**
- Source: PharmiWeb.com | 20251211T160554 | Bullish | Relevance: 100%
- Charles River Laboratories announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP), supporting early-stage biotechnology with scientific expertise and development capabilities. The program features four advanced therapy developers and two enabling technology developers, aiming to accelerate the creation of life-changing therapies. Participants receive mentorship, regulatory guidance, and access to Charles Riverâ€™s global network to advance their programs from concept to cure.

**4. Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort**
- Source: Business Wire | 20251211T130801 | Bullish | Relevance: 100%
- Charles River Laboratories International, Inc. (NYSE: CRL) has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). This program offers early-stage biotechnology companies access to Charles River's scientific expertise, development capabilities, and manufacturing resources to accelerate advanced therapy development. The cohort includes four advanced therapy developers and two enabling technology developers, benefiting from tailored mentorship, regulatory expertise, and facility access, aiming to transform innovative ideas into impactful treatments.

**5. Charles River (NYSE: CRL) names 6 firms to cell & gene therapy incubator, opens 2026 apps**
- Source: Stock Titan | 20251211T130149 | Bullish | Relevance: 100%
- Charles River Laboratories International, Inc. (NYSE: CRL) has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP), selecting six companies focused on advanced therapy development and enabling technologies. The program aims to accelerate the development of life-changing therapies by providing scientific and commercial expertise, regulatory guidance, and access to Charles River's global network and manufacturing capabilities. Applications for the 2026 cohort are now open, continuing Charles River's commitment to supporting early-stage biotechnology innovators.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 17.6x stretched relative to 7% growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.64 |
| 52W Range | $91.86 - $199.66 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 17.6 |
| Current P/E | 18.9 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 5.9% to 8.4% (+2.5% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 91st percentile. MRS_5 at 2.4% confirms short-term momentum alignment. AM_20 at 8.8% shows strong absolute momentum above own 20MA. Outperforming sector by 8.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.07), confirming momentum. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.45% (CS: 91) | Strong |
| RSI_14 | 67.4 | Neutral |
| MACD Histogram | 2.07 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.089x | Above |
| vs SMA200 | 1.233x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $193.03
- **Stop Loss:** $180.79 (6.3% risk)
- **Target:** $217.51 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $15,635.43
- **Portfolio %:** 15.64%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*